Saccharomyces boulardii induced sepsis: Successful therapy with voriconazole after treatment failure with fluconazole

References

• Kwong-Chung KJ, Bennett JE. Saccharomyces Meyen Ex Reess. In: Kwong-Chung KJ, Bennett JE, editors. Medical mycology. Philadelphia: Lea and Febiger; 1992. p. 772–3.
   Google Scholar
• Murphy A, Kavanagh K. Emergence of Saccharomyces cerevisiae as a human pathogen: implications for biotechnology. Enzyme Microbial Technol 1999;25:551–7.
   Web of Science ®Google Scholar
• McFarland LV. Saccharomyces cerevisiae is not Saccharomyces boulardii. Clin Inf Dis 1996;22:200–1.
   PubMed Web of Science ®Google Scholar
• Golledge CL, Riley TV. Natural therapy for infectious diseases. Med J Aust 1996;164:94–5.
   PubMedGoogle Scholar
• Lewis SJ, Freedman AR. Review article: the use of biother- apeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807–22.
   PubMed Web of Science ®Google Scholar
• Sullivan A, Nord CE. Probiotics in human infections. J Antimicrob Chemother 2002;50:625–7.
   PubMed Web of Science ®Google Scholar
• Anaissie E, Bodey GP, Kantarjian H, Ro J, Vartivarian SE, Hopfer R, et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989;11:369–78.
   PubMedGoogle Scholar
• Krcmery V, Krupova I, Denning DW. Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect 1999;41:181–94.
   Google Scholar
• Salonen JH, Richardson MD, Gallacher K, Issakainen J, Helenius H, Lehtonen OP, Nikoskelainen J. Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae. J Hosp Infect 2000;45:293–301.
   Google Scholar
• Lherm T, Monet C, Nougiere B, Soulier M, Larbi D, Le Gall C, et al. Seven cases of fungaemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28:797–801.
   Google Scholar
• Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study. Gastroenterol 1989;96:981–8.
   Google Scholar
• McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile diseases. JAMA 1994;271:1913–8.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, et al. Prevention of ß-lactam- associated diarrhoea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439–48.
   PubMed Web of Science ®Google Scholar
• Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhoea in critically ill tube-fed patients. A multicentre, randomized, double-blind placebo controlled trial. Intensive Care Med 1997;23:517–23.
   Google Scholar
• Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces bou- lardii. Clin Inf Dis 2000;31:1012–7.
   PubMed Web of Science ®Google Scholar
• Eschete ML, West BC. Saccharomyces cerevisiae septicaemia. Arch Intern Med 1980;140:1539.
   PubMed Web of Science ®Google Scholar
• Aucott JN, Fayen J, Grossnicklas H, Morrissey A, Lederman MM, Salata RA. Invasive infection with Saccharomyces cerevisiae: report of 3 cases and review. Rev Infect Dis 1990;12:406–11.
   PubMedGoogle Scholar
• Doyle MG, Pickering LK, O’Brien N, Hoots K, Benson JE. Saccharomyces cerevisiae infection in a patient with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1990;9: 850–1.
   Google Scholar
• Muehrcke DD, Lytle BW, Cosgrove DM 3rd. Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg 1995;60:538–43.
   Google Scholar
• Smith D, Metzgar D, Wills C, Fierer J. Fatal Saccharomyces cerevisiae aortic graft infection. J Clin Microbiol 2002;40: 2691–2.
   PubMed Web of Science ®Google Scholar
• Posteraro B, Sanguinetti M, D’Amore G, Masucci L, Morace G, Fadda G. Molecular and epidemiological characterization of vaginal Saccharomyces cerevisiae isolates. J Clin Microbiol 1999;37:2230–5.
   Google Scholar
• Jabra-Rizk MA, Ferreira SM, Sabet M, Falkler WA, Merz WG, Meiller TF. Recovery of Candida dubliniensis and other yeasts from human immunodeficiency virus- associated periodontal lesions. J Clin Microbiol 2001;39: 4520–2.
   Google Scholar
• Krogh P, Holmstrup P, Vedtofte P, Pindborg JJ. Yeast organisms associated with human oral leukoplakia. Acta Derm Venereol 1986;121:51–5.
   Google Scholar
• Cairoli R, Marenco P, Perego R, de Cataldo F. Saccharomyces cerevisiae fungaemia with granulomas in the bone marrow in a patient undergoing BMT. Bone Marrow Transplant 1995;15:785–6.
   PubMed Web of Science ®Google Scholar
• Pletinex M, Legein J, Vandenplas Y. Fungaemia with Saccharomyces boulardii in a 1-y-old girl with pretreated diarrhoea. J Pediadr Gastroenterol Nutr 1995;21: 113–5.
   Google Scholar
• Viggiano M, Badetti C, Bernini V, Garabedian M, Manelli JC. Saccharomyces boulardii fungaemia in a patient with severe burns. Ann Fr Anesth Reanim 1995;14:356–8.
   PubMed Web of Science ®Google Scholar
• Bassetti S, Frei R, Zimmerli W. Fungaemia with Saccharomyces cerevisiae after treatment with Saccharomyces bou- lardii. Am J Med 1998;105:71–2.
   Google Scholar
• Fiore NF, Conway JH, West KW, Kleiman MB. Saccharomyces cerevisiae infections in children. Pediatr Infect Dis J 1998;17:1177–9.
   PubMedGoogle Scholar
• Fredenucci I, Chomarat M, Boucaud C, Flandrois JP. Saccharomyces boulardii fungaemia in a patient receiving ultra-levure therapy. Clin Inf Dis 1998;27:222–3.
   PubMed Web of Science ®Google Scholar
• Niault M, Thomas F, Prost J, Ansari FH, Kalfon P. Fungaemia due to Saccharomyces boulardii in a patient treated with enteral Saccharomyces boulardii. Clin Inf Dis 1999;28:930.
   Google Scholar
• Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungaemia in a neutropenic patient treated with Saccharomyces bourlardii. Support Care Cancer 2000;8: 504–5.
   PubMed Web of Science ®Google Scholar
• Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard J P, Ricour C, Jacquemin JL, Berche P. Possible role of catheters in Saccharomyces boulardii fungaemia. Eur J Clin Microbiol Infect Dis 2000;19:16–20.
   PubMed Web of Science ®Google Scholar
• Perapoch J, Planes AM, Querol A, Lopez V, Martinez- Bendayan I, Tormo R, et al. Fungaemia with Saccharomyces cerevisiae in 2 newborns, 1 of whom had been treated with ultra-levura. Eur J Clin Microbiol Dis 2000;19: 468–70.
   Google Scholar
• Rijnders BJ, van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungaemia complicating Saccharomyces boulardii treatment in a non-immunocompromized host. Intensive Care Med 2000;26:825.
   PubMed Web of Science ®Google Scholar
• Cassone M, Serra P, Mondello F, Girolamo A, Scafetti S, Pistella E, Venditti M. Outbreak of Saccharomyces cerevisiae subtype boulardii fungaemia in patients neighbouring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003;41:5340–3.
   Google Scholar
• Riquelme AJ, Calvo MA, Guzman AM, Depix MS, Garcia P, Perez C, et al. Saccharomyces cerevisiae fungaemia after Saccharomyces boulardii treatment in immuncompro- mized patients. J Clin Gastroenterol 2003;36:41–3.
   PubMed Web of Science ®Google Scholar
• Lestin F, Pertschy A, Rimak D. Fungaemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities. Dtsch Med Wochenschr 2003;28: 2531–3.
   Google Scholar
• Zerva L, Hollis RJ, Pfaller MA. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates. J Clin Microbiol 1996;34:3031–4.
   Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Inf Dis 2003;36:630–7.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less- common, emerging, or refractory fungal infections. Clin Inf Dis 2003;36:1122–31.
   Google Scholar
• Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109–496) against opportunistic filamentous and dimorphic fungi and common emerging yeast pathogens. J Clin Microbiol 1998;36:198–202.
   PubMed Web of Science ®Google Scholar